Abstract
Single-nucleotide polymorphisms of the genes for mitochondrial (SOD2) and extracellular (SOD3) superoxide dismutases were tested for association with diabetic polyneuropathy (DPN) in diabetes mellitus (DM) type 1. Patients (N = 180) were divided into two groups with nonoverlapping (polar) phenotypes. Group DPN+ included 86 individuals with DPN and DM type 1 record of no more than 5 years. Group DPN– included 94 patients with DM type 1 record of more than 10 years but without clinical signs of DPN. Fisher's exact test revealed significant differences in allele and genotype frequencies for the two groups. Higher frequencies of SOD2 allele Val and genotype Val/Val and of SOD3 allele Arg and genotype Arg/Arg were established for group DPN+. On this evidence, SOD2 and SOD3 were associated with DPN in DM type 1.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
De Los Rios M.G., Durruty P. 1999. Pathophysiology of diabetic nephropathy. Diabetografiya. 13, 2-5.
Ceriello A. 1999. Pathophysiological mechanisms of vascular complications in diabetes mellitus-role of oxidative stress. Medikografiya. 21, 25-28.
Zhu M., Spink D.C., Yan B., Bank S., DeCaprio A.P. 1994. Formation and structure of crosslinking and monomeric pyrrole autooxidation products in 2,5-hex-anedione-treated amino acids, peptides, and protein. Chem. Res. Toxical. 7, 551–558.
Cameron N.E., Cotter M.A. 1997. Metabolic and vascu-lar factors in the pathogenesis of diabetic neuropathy. Diabetes. 46, 31–37.
Kumar J.S., Menon V.P. 1992. Peroxidative changes in experimental diabetes mellitus. Indian J. Med. Res.. 96, 176–181.
Van Dam P.S., Van Asbeck B.S., Erkelens D.W., Marx J.J.M., Gispen W.-H., Bravenboer B. 1995. The role of oxidative stress in neuropathy and other diabetic complications. Diabetes metabolism reviews. 11, 181–192.
Van Dam P.S., Van Asbeck B.S., Bravenboer B., Van Oir-schot J.F., Marx J.J.M., Gispen W.-H. 1999. Nerve conduction and antioxidant levels in experimentally diabetic rats: effects of streptozotocin dose and diabetes duration. Metabolism. 48, 442–447.
Martinez-Blasco A., Bosch-Morell F., Trenor C., Romero F.J. 1998. Experimental diabetic neuropathy: role of oxidative stress and mechanisms involved. Bio-factors. 8, 41–43.
Marklund S.L. 1990. Analysis of extracellular superox-ide dismutase in tissue homogenates and extracellular fluids. Methods Enzymol. 186, 260–265.
Shimoda-Matsubayashi S., Matsumine H., Kobayashi T., Nakagawa-Hattori Y., Shimiz Y., Mizino Y. 1996. Structural dimorphism in the mitochondrial argeting sequence in the human manganese superoxide dismutase gene. Biochem. Biophys. Res. Commun. 226, 561–565.
Shimoda-Matsubayashi S., Hattori Y., Matsumine H., Shinohara A., Yoritaka A., Mori H., Kondo T., Chiba M., Mizuno Y. 1997. MnSOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkin-sonism in comparison with Parkinson's disease and con-trol. Neurology. 49, 1257–1262.
Rosenblum J.S., Gilla N.B., Lerner R.A. 1996. On signal sequence polymorphisms and diseases of distribution. Proc. Natl. Acad. Sci. USA. 93, 4471–4473.
Sandstrom J., Nilson P., Karlsson K., Marklund S.L. 1994. 10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. J. Biol. Chem. 269, 19163–19166.
Folz R.J., Peno-Green L., Grapo J.D. 1994. Identification of a homozygous missense mutation (Arg to Gly) in the critical binding region of the human EC-SOD gene (SOD3) and its association with dramatically increased serum enzyme levels. Hum. Mol. Genet. 12, 2251–2254.
Yamada H., Yamada Y., Adachi T., Goto H., Ogasawara N., Futenma A., Kitano M., Hirano K., Kato K. 1995. Molecular analysis of extracellular-superoxide dismutase gene associated with high level in serum. Jpn. Hum. Genet. 40, 177–184.
Sakashita N., Ando Y., Marklund S.L., Nilsson P., Tashi-ma K., Yamashita T., Takahashi K. 1998. Familial amyloidotic polyneuropathy type I with extracellular super-oxide dismutase mutation: a case report. Hum. Pathol. 29, 1169–1172.
Strokov I.A., Novosadova M.V., Baranov A.N., Yakhno N.N. 2000. Clinical assessment of severity of diabetic polyneuropathy. Nevrol. Zh. 5, 14-18.
Dyck P.J., Melton J.L., O'Brien P.C., Service F.G. 1997. Approaches to improve epidemiological studies of diabetic neuropathy: insights from the Rochester Diabetic Neuropathy Study. Diabetes. 46, 5–8.
Komantsev V.N., Zabolotnykh V.A. 2001. Basic Methods of Clinical Electroneuromyography. A Manual. St. Petersburg.
Budowle B., Baechtel F.S. 1990. Modifications to improve the effectiveness of restriction fragment length polymorphism. Appl. Electrophor. 1, 181–187.
Chistyakov D.A., Savost'anov K.V., Zotova E.V., Strokov I.A., Nosikov V.V. 2001. Polymorphisms at the SOD2 and SOD3 genes and their relation to diabetic neuropathy in type 1 diabetes mellitus. BMC Medical Genetics. 2, 4–11.
Hutchon D.J.R. http:// Calculator for confidence intervals for odds ratio unmatched case control study.
Hiroi S., Harada H., Nishi H., Satoh M., Nagai R., Kimura A. 1999. Polymorphisms in the SOD2 and HLA-DRB1 genes are associated with nonfamilial idiopathic dilated cardiomyopathy in Japanese. Biochem. Biophys. Res. Commun. 261, 332–339.
Marklund S.L. 1984. Extracellular superoxide dismutase in human tissues and human cell lines. Clin. Invest. 74, 1398–1403.
Wang X.L., Adachi T., Sim A.S., Wilcken D.E. 1998. Plasma extracellular superoxide dismutase levels in an Australian population with coronary artery disease. Atheroscler. Thromb. Vasc. Biol. 18, 1915–1921.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zotova, E.V., Chistyakov, D.A., Savost'yanov, E.V. et al. Association of the SOD2 Ala(–9)Val and SOD3 Arg213Gly Polymorphisms with Diabetic Polyneuropathy in Diabetes Mellitus Type 1. Molecular Biology 37, 345–348 (2003). https://doi.org/10.1023/A:1024222907542
Issue Date:
DOI: https://doi.org/10.1023/A:1024222907542